Peachey J E, Annis H M, Bornstein E R, Sykora K, Maglana S M, Shamai S
Br J Addict. 1989 Aug;84(8):877-87. doi: 10.1111/j.1360-0443.1989.tb00760.x.
A randomized, double-blind, placebo-controlled single cross-over study of the alcohol sensitizing drug, calcium carbimide (CC), was conducted in 128 patients with alcohol dependence. Seventy-one (55%) completed the 4-month study. Patients reported drinking and pill-taking behaviour, and submitted urines (for analysis of alcohol and the tablet marker riboflavin) on 97%, and 91% of treatment days, respectively. All of the 69 analyzable completers were abstinent on at least 85% of days, and 58% (40) were alcohol-free during the study. Medications were taken on at least 85% of days. Symptoms and adverse clinical findings were not increased in frequency during CC, compared to placebo. Seventy-eight per cent of the patients believed they had received CC throughout the study, suggesting that CC exerts a strong psychological deterrent effect. Alcohol consumption was significantly reduced to the same extent with CC and placebo, compared to pre-treatment levels.
对128例酒精依赖患者进行了一项关于酒精增敏药物卡马咪嗪（CC）的随机、双盲、安慰剂对照单交叉研究。71例（55%）完成了为期4个月的研究。患者分别在97%和91%的治疗日报告饮酒和服药行为，并提交尿液（用于分析酒精和片剂标记物核黄素）。69例可分析的完成者在至少85%的日子里戒酒，58%（40例）在研究期间完全戒酒。至少85%的日子里服用了药物。与安慰剂相比，服用CC期间症状和不良临床发现的频率没有增加。78%的患者认为他们在整个研究过程中服用的是CC，这表明CC具有很强的心理威慑作用。与治疗前水平相比，CC和安慰剂使酒精摄入量均显著降低至相同程度。
